SCHEMBL25921173

SCHEMBL25921173

CN1C(=O)CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)N4CCCC4)c(Cl)c3)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 9/20 0.53
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ CNR2 P34972 2/20 0.51
▸ LMNA P02545 4/20 0.50
▸ TP53 P04637 4/20 0.50
▸ POLB P06746 3/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ ESR1 P03372 1/20 0.49
▸ ESR2 Q92731 1/20 0.49
▸ MAPK1 P28482 3/20 0.48
▸ ALOX15 P16050 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ USP2 O75604 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ CNR1 P21554 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25921176 0.99 CNR2 (0.52) MAPTMEN1KMT2ACNR2LMNA
SCHEMBL25922077 0.90 MAPT (0.56) MAPTMEN1KMT2ALMNATP53
SCHEMBL24125084 0.89 MAPT (0.61) MAPTMEN1KMT2ACNR2LMNA
SCHEMBL24124800 0.88 MAPT (0.62) MAPTMEN1KMT2ACNR2LMNA
SCHEMBL30270587 0.87 CYP1A2 (0.58) MAPTMEN1KMT2ALMNATP53
SCHEMBL25921866 0.87 CYP1A2 (0.58) MAPTMEN1KMT2ALMNATP53
SCHEMBL25930932 0.86 MAPT (0.52) MAPTMEN1KMT2ALMNATP53
SCHEMBL25921495 0.84 CNR2 (0.49) MAPTMEN1KMT2ACNR2LMNA
SCHEMBL24124823 0.83 MAPT (0.55) MAPTMEN1KMT2ALMNATP53
SCHEMBL24125094 0.82 LMNA (0.59) MAPTMEN1KMT2ALMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885MEN1 2558/4885KMT2A 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback